Views

CrossRef citations to date

Altmetric

Letters to the Editor

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Marina Deodatoa Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyCorrespondence[email protected]

https://orcid.org/0000-0003-0010-6107

Anna Maria Frustacia Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Paolo Sportolettib Department of Medicine and Surgery, Institute of Hematology, Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy

Luca Laurentic Institute of Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

Roberta Murrud Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, Cagliari, Italy

Andrea Visentine Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy

Gianluigi Redaf U.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy

Francesca Romana Maurog Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Roma, Italy

Giulia Quaresminih USC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy

Anna Vanazzii Division of Clinical Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy

Candida Vitalej Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, Università di Torino, Torino, Italy

https://orcid.org/0000-0002-2592-8724

Lorella Orsuccik S.C. Ematologia, AOU Città della Salute e della Scienza, Torino, Italy

Massimo Massaial Hematology Unit, ASO Santa Croce e Carle, Cuneo, Italy

Alessandro Sannam Hematology, Department of Oncology, AOU Careggi, Florence, Italy

Marina Mottan Hematology Department, ASST Spedali Civili, Brescia, Italy

Adalberto Ibaticio Hematology Unit and Bone Marrow Transplantation, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Isacco Ferrarinip Department of Medicine, Section of Hematology, University of Verona, Verona, Italy

Chiara Borellaq Hematology Department, San Gerardo Hospital, ASST Monza, Monza, Italy

Marzia Varettonir Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Monica Tanis U.O.C. di Ematologia Ospedale Santa Maria delle Croci, Ravenna, Italy

Sara Marinonit UOC Ematologia, ASST Ovest milanese, Ospedale di Legnano, Legnano, Italy

Andrea Ferrariou UO Ematologia, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy

Giulia Zamprognaa Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Marco Montilloa Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Alessandra Tedeschia Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

show all

References

Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354–2363.
PubMed Web of Science ®Google Scholar
Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143.
PubMed Web of Science ®Google Scholar
Calderón-Parra J, Múñez-Rubio E, Fernández-Cruz A, et al. Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2021;ciab700.
Google Scholar
COVID-19 and CLL: frequently asked questions (version 4.1); 2021; [cited 2021 Feb 4]. Available from: www.hematology.org/covid-19/covid-19-and-cll
Google Scholar
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
PubMed Web of Science ®Google Scholar
Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date